Structure Therapeutics Inc (GPCR) FinancialsGPCRFinancialStructure Therapeutics Inc

Evaluating the bottom line, Structure Therapeutics Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -20.21%, provide a clear picture of how effectively GPCR converts its operational activities into shareholder value.

In the context of the broader market, GPCR competes directly with industry leaders such as TARS and OGN. With a market capitalization of $3.89B, it holds a leading position in the sector. When comparing efficiency, GPCR's gross margin of N/A stands against TARS's 93.03% and OGN's 54.36%. Such benchmarking helps identify whether Structure Therapeutics Inc. is trading at a premium or discount relative to its financial performance.

The company reported a net income loss of $106,159,000 in Q2 2026, continuing a trend of negative earnings, with an EPS of -0.49, which is worse than the estimated -0.39. The forward P/E is 0, indicating no expected earnings growth in the near term.